🚀 Announcing our new multi-year data license agreement with @GSK to investigate the drivers of #liverdisease! . Read the announcement ➡️ .

4.5M US adults live with chronic liver disease, & transplant demand far outpaces donors. In a recent @MayoClinic video, Dr. Bashar Aqel talks about the anxious waits for life-saving surgery that many patients face while their conditions deteriorate. 🎥

The NHS 10-Year Plan signals a shift toward earlier intervention, genomics, & smarter care systems. It’s great to see a national strategy reflect the importance of understanding disease biology & using AI to build more efficient, data-rich systems.

Liver therapies are undergoing their most significant disruption in decades. In @thetimes, @Quin_Wills discusses how metabolic drugs like Wegovy & Mounjaro are moving us from symptom control to targeted therapies. Read the full article:

RT @healthtechworld: Oxford-based @OchreBio, a biotechnology company developing RNA therapeutics for chronic liver disease, has appointed D….

AI is reshaping how we diagnose and treat disease. In @DailyMailUK, @LaraLewington explores this shift, featuring our work using machine learning and human liver data to develop RNA therapies for late-stage disease. Article 👉

🎉 Huge congratulations to the Ochre team who completed Sunday’s @raceforlife for @CR_UK!. Support the team here👉

Announcing Dr. @QuinWills as the new CEO of Ochre Bio 👏 . As founder & former CSO, Quin has shaped our RNA therapy strategy from day one. He now leads Ochre into it's next phase: progressing new drug candidates toward the clinic. 🔗

In just 6 years, Jenna went from managing an autoimmune condition to liver failure. She got a transplant just in time – but many aren't as lucky. A powerful reminder of how fast liver disease can progress and how long the wait for transplant can be. 🔗

We've been included in @BloombergUK & @Founders_Forum's 25 European companies to watch in 2025!. Grateful to be highlighted for our work in advanced liver disease, alongside other innovative companies in genAI, auto vehicles, space & biotech.🚀. Full list➡️

Rezdiffra is showing promise in compensated MASH cirrhosis. At #EASL, Madrigal shared 2-year data: 65% of patients with CSPH at baseline moved to lower-risk categories. Fibrosis markers, liver stiffness and portal pressure also improved. 🔗

Read the Lancet study 👉

Over 15 million in the US, UK, Germany & France may be living with MASH & don’t know it. That means higher risk of chronic liver disease without diagnosis or treatment. Early detection is vital, but we also need better ways to treat what we find. 🔗

Among the jam-packed conference schedule, Quin also sat down with Nasdaq’s Elsa Givan to share his vision for 2030 – including a rapid-fire Q&A on curiosity, creativity, and biotech’s future. Thanks @sxswlndn for the opportunity to share our science!.

However, for Quin, this work is personal. His path as a biotech founder and his experience as a patient with liver disease all drive his focus on developing effective therapies for chronic liver disease.

That was the thread running through our Founder @QuinWills' talk at @sxswlndn – on a stage next to a perfused human liver and some big questions about how we treat liver disease.

Great AI in drug R&D needs great human data. While algorithms deserve the glory they're receiving, the true pioneers are the scientists figuring out novel ways to produce translatable human data. Watch the presentation:

🩺 In 2005, Anthony was told he had “fatty liver”, which came with no warning signs. After 9 yrs of fat buildup, he learned he had cirrhosis & liver cancer. He had felt fine the whole time. Stories like this remind us of how silent liver disease can be. 🔗

AI in drug discovery is no longer a ‘what if’. It’s here. What’s changing is what drives value. A new @Nature biopharma dealmakers piece highlights our innovative collaboration with @GSK & how deals are shifting toward high-quality human data. Read:

🚨 @Quin_Wills is on stage today at #SXSWLondon. 🕒 14:30–14:55 | Truman Brewery Stage 1. He’ll share how we combine machine learning with human-first lab models to move beyond animal testing & improve drug discovery for liver disease. Dont miss out 👉

📊 Weight-loss medications are showing significant benefits, particularly for liver health. In @thetimes, our Founder & CSO @QuinWills explores what this means for liver disease & cirrhosis, & why these first-gen therapies are only part of the story. 🔗